HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on CollPlant Biotechnologies (NASDAQ:CLGN) and maintained an $11 price target.
August 25, 2023 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CollPlant Biotechnologies (NASDAQ:CLGN) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $11.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $11 indicates the firm's confidence in the stock's potential to reach this price in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100